Data gathered: February 1
AI Stock Analysis - Amylyx Pharmaceuticals (AMLX)
Analysis generated September 6, 2024. Powered by Chat GPT.
Amylyx Pharmaceuticals is a biotechnology company that focuses on developing novel treatments for neurodegenerative diseases such as ALS (Amyotrophic Lateral Sclerosis) and Alzheimer’s disease. The company aims to address significant unmet medical needs with its innovative therapeutic approaches.
Stock Alerts - Amylyx Pharmaceuticals (AMLX)
 |
Amylyx Pharmaceuticals | January 31 Price is up by 5.1% in the last 24h. |
|
Amylyx Pharmaceuticals | January 28 Price is down by -5.6% in the last 24h. |
|
Amylyx Pharmaceuticals | January 22 Price is down by -5.5% in the last 24h. |
|
Amylyx Pharmaceuticals | January 21 Price is down by -8.3% in the last 24h. |
Alternative Data for Amylyx Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 4 | Sign up | Sign up | Sign up |
| Facebook Followers | 508 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,193 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,947 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 47 | Sign up | Sign up | Sign up |
| Linkedin Employees | 189 | Sign up | Sign up | Sign up |
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases.
| Price | $3.65 |
| Target Price | Sign up |
| Volume | 1,390,000 |
| Market Cap | $301M |
| Year Range | $1.62 - $7.03 |
| Dividend Yield | 0% |
| Analyst Rating | 60% buy |
| Industry | Biotechnology |
In the news
 |
FY2025 Earnings Forecast for AMLX Issued By Leerink PartnrsJanuary 31 - ETF Daily News |
|
JPMorgan Chase & Co. Has $455,000 Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)January 29 - ETF Daily News |
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Position Trimmed by Hennion & Walsh Asset Management Inc.January 22 - ETF Daily News |
|
Barclays PLC Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)January 21 - ETF Daily News |
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral SclerosisJanuary 20 - Finnhub |
|
|
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives $7.33 Consensus Price Target from BrokeragesJanuary 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 420,000 | 18M | -17M | -73M | -76M | -1.070 |
| Q2 '24 | -1M | 45M | -46M | -73M | -53M | -0.730 |
| Q1 '24 | 89M | 64M | 25M | -119M | -122M | -0.120 |
| Q4 '23 | 108M | 62M | 47M | 4.7M | 2.2M | 0.070 |
| Q3 '23 | 103M | 54M | 49M | 21M | 19M | 0.300 |
Insider Transactions View All
| Cohen Joshua B filed to sell 3,213,098 shares at $4. January 8 '25 |
| Klee Justin B. filed to sell 3,176,788 shares at $4. January 8 '25 |
| Bedrosian Camille L filed to sell 138,380 shares at $5.5. December 3 '24 |
| Mazzariello Gina filed to sell 142,768 shares at $3.2. October 2 '24 |
| Bedrosian Camille L filed to sell 143,801 shares at $3.2. October 2 '24 |
Similar companies
Read more about Amylyx Pharmaceuticals (AMLX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Amylyx Pharmaceuticals?
The Market Cap of Amylyx Pharmaceuticals is $301M.
What is the current stock price of Amylyx Pharmaceuticals?
Currently, the price of one share of Amylyx Pharmaceuticals stock is $3.65.
How can I analyze the AMLX stock price chart for investment decisions?
The AMLX stock price chart above provides a comprehensive visual representation of Amylyx Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Amylyx Pharmaceuticals shares. Our platform offers an up-to-date AMLX stock price chart, along with technical data analysis and alternative data insights.
Does AMLX offer dividends to its shareholders?
As of our latest update, Amylyx Pharmaceuticals (AMLX) does not offer dividends to its shareholders. Investors interested in Amylyx Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Amylyx Pharmaceuticals?
Some of the similar stocks of Amylyx Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.